%0 Generic %A Pereira, Tais Susane %A de Sant’anna, Juliane Rocha %A Morais, Janicelle Fernandes %A de Sant’anna Yajima, Joana Paula Rocha %A Cezar de Freitas Mathias, Paulo %A Conationi da Silva Franco, Claudinéia %A Avezum Alves de Castro-Prado, Marialba %D 2018 %T Assessment of bendamustine-induced genotoxicity in eukaryotic cells %U https://tandf.figshare.com/articles/dataset/Assessment_of_bendamustine-induced_genotoxicity_in_eukaryotic_cells/6635438 %R 10.6084/m9.figshare.6635438.v1 %2 https://tandf.figshare.com/ndownloader/files/12149210 %2 https://tandf.figshare.com/ndownloader/files/12149213 %K Alkylating agents %K cytotoxicity %K in vitro mammalian cells micronucleus test %K chromosome aberrations test %K mitotic recombination %K human peripheral lymphocytes %X

Bendamustine, an anticancer drug with alkylating properties, is widely used to treat hematological malignancies. Since the nitrogen mustard family alkylators induce DNA damages and have been associated with an elevated risk of second malignancy, current study evaluates the cytotoxic, mutagenic, and recombinogenic effects of bendamustine by using, respectively the mitotic index assay, the in vitro mammalian cell micronucleus test (Mnvit) and the chromosome aberration (CA) test in human peripheral lymphocytes, and the in vivo homozygotization assay in Aspergillus nidulans, which detects the loss of heterozygosity (LOH) due to somatic recombination. Bendamustine (6.0 µg/ml, 9.0 µg/ml, and 12.0 µg/ml) induced a statistically significant concentration-related increase in the frequencies of micronuclei and a significant reduction in the cytokinesis block proliferation index (CBPI) rates when compared to negative control. In the CA test, bendamustine significantly increased the frequencies of structural aberrations at the three tested concentrations when compared to the negative control. Aspergillus nidulans diploids, obtained after bendamustine treatment (6.0 µg/ml, 12.0 µg/ml, and 24.0 µg/ml), produced, after haploidization, homozygotization index (HI) rates higher than 2.0 and significantly different from the negative control. Since bendamustine showed genotoxic effects in all tested concentrations, two of them corresponding to the peak plasma concentrations observed in cancer patients treated with bendamustine, data provided in the current research work may be useful to identify the most appropriate dosage regimen to achieve the efficacy and safety of this anticancer medication.

%I Taylor & Francis